IL104179A - Process for the preparation of solid pharmaceutical dispersions and solid pharmaceutical dispersions with improved solubility characteristics - Google Patents

Process for the preparation of solid pharmaceutical dispersions and solid pharmaceutical dispersions with improved solubility characteristics

Info

Publication number
IL104179A
IL104179A IL104179A IL10417992A IL104179A IL 104179 A IL104179 A IL 104179A IL 104179 A IL104179 A IL 104179A IL 10417992 A IL10417992 A IL 10417992A IL 104179 A IL104179 A IL 104179A
Authority
IL
Israel
Prior art keywords
solid pharmaceutical
pharmaceutical dispersions
preparation
drug
improved solubility
Prior art date
Application number
IL104179A
Other languages
English (en)
Other versions
IL104179A0 (en
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL104179A0 publication Critical patent/IL104179A0/xx
Publication of IL104179A publication Critical patent/IL104179A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Glanulating (AREA)
  • Ceramic Products (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
IL104179A 1991-12-18 1992-12-18 Process for the preparation of solid pharmaceutical dispersions and solid pharmaceutical dispersions with improved solubility characteristics IL104179A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80965691A 1991-12-18 1991-12-18

Publications (2)

Publication Number Publication Date
IL104179A0 IL104179A0 (en) 1993-05-13
IL104179A true IL104179A (en) 1997-11-20

Family

ID=25201894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL104179A IL104179A (en) 1991-12-18 1992-12-18 Process for the preparation of solid pharmaceutical dispersions and solid pharmaceutical dispersions with improved solubility characteristics

Country Status (17)

Country Link
US (3) US6677362B1 (es)
EP (1) EP0617612B1 (es)
JP (1) JP3722293B2 (es)
AT (1) ATE157864T1 (es)
AU (1) AU671811B2 (es)
CA (1) CA2124821C (es)
DE (1) DE69222182T2 (es)
DK (1) DK0617612T3 (es)
ES (1) ES2109377T3 (es)
GR (1) GR3025501T3 (es)
IL (1) IL104179A (es)
MX (1) MX9207390A (es)
NZ (1) NZ245483A (es)
PT (1) PT101132B (es)
SG (1) SG43179A1 (es)
WO (1) WO1993011749A1 (es)
ZA (1) ZA929789B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
WO1995013794A1 (fr) * 1993-11-18 1995-05-26 Nippon Shinyaku Co., Ltd. Procede pour produire une composition de medicament stable, et preparation pharmaceutique
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
US6376542B1 (en) * 1997-12-19 2002-04-23 Bissell Homecare, Inc. Aqueous miticide compositions containing benzyl benzoate
US6107341A (en) * 1997-12-19 2000-08-22 Bissell Homecare, Inc. Aqueous miticide containing benzyl benzoate
DE69821984T2 (de) * 1997-12-22 2004-12-30 Schering Corp. Zubereitung enthaltend eine molekulardispersion mit erhöhter bioverfügbarkeit
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
EP1183017A1 (en) * 1999-05-28 2002-03-06 Abbott Laboratories Novel formulations comprising lipid-regulating agents
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP2004534822A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 低溶解度および／または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
AU2002242339A1 (en) * 2002-03-14 2003-09-29 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004000263A1 (en) 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
US8486447B2 (en) * 2003-02-03 2013-07-16 Novartis Ag Pharmaceutical formulation
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
ATE406946T1 (de) * 2003-04-29 2008-09-15 Organon Nv Verfahren zur verfestigung, bei welchem ein anti- lösungsmittel benutzt wird
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8273371B2 (en) 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
EP1871346A4 (en) * 2005-04-20 2012-07-18 Ctc Bio Inc PHARMACEUTICAL COMPOSITION WITH FREE BASE FROM SIBUTRAMIN AND MANUFACTURING METHOD THEREFOR
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
DE102005023803A1 (de) * 2005-05-19 2006-11-23 Basf Ag Verfahren zur Herstellung von festen Blends aus Polyvinylpyrrolidonen und ethoxilierten Fettsäurederivaten
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080132560A1 (en) * 2006-11-21 2008-06-05 San-Laung Chow Solid dispersion composition
US20100016449A1 (en) * 2006-12-21 2010-01-21 Boehringer Ingelheim International Gmbh Formulations with Improved Bioavailability
PE20091550A1 (es) * 2008-01-11 2009-10-03 Cipla Ltd Composicion farmaceutica extruida/granulada en caliente
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
MX2012000369A (es) 2009-07-22 2012-02-01 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion.
CN113274355B (zh) * 2009-10-27 2023-05-30 鲁平有限公司 利福昔明固体分散体
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
CN103179959A (zh) 2010-10-20 2013-06-26 帝斯曼知识产权资产管理有限公司 含悬挂亲水基的可生物降解的组合物和相关器械
JP6068352B2 (ja) * 2010-10-29 2017-01-25 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む固体分散体
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PT2736495T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente à adulteração proporcionando libertação imediata de fármaco
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
BR112015029616A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem resistente à adulteração com perfil de liberação bimodal
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US10085991B2 (en) 2014-12-04 2018-10-02 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN113616599B (zh) * 2021-09-10 2022-11-18 宁夏医科大学 一种大黄素固体分散体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000091A1 (en) * 1981-07-08 1983-01-20 Keith, Alec, Dell Polymeric diffusion matrix containing 5-ad(3,4-dimethoxyphenethyl)methylaminobd-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
DE3839825A1 (de) * 1988-11-25 1990-06-13 Henning Berlin Gmbh Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion

Also Published As

Publication number Publication date
IL104179A0 (en) 1993-05-13
US20040110694A1 (en) 2004-06-10
DE69222182T2 (de) 1998-02-26
ES2109377T3 (es) 1998-01-16
JP3722293B2 (ja) 2005-11-30
US6677362B1 (en) 2004-01-13
AU671811B2 (en) 1996-09-12
NZ245483A (en) 1995-12-21
SG43179A1 (en) 1997-10-17
US20010044409A1 (en) 2001-11-22
CA2124821C (en) 2003-10-07
EP0617612B1 (en) 1997-09-10
ZA929789B (en) 1993-06-23
DE69222182D1 (de) 1997-10-16
GR3025501T3 (en) 1998-02-27
CA2124821A1 (en) 1993-06-24
ATE157864T1 (de) 1997-09-15
MX9207390A (es) 1993-06-01
PT101132B (pt) 2000-02-29
JPH07504162A (ja) 1995-05-11
EP0617612A1 (en) 1994-10-05
PT101132A (pt) 1994-03-31
AU3142693A (en) 1993-07-19
DK0617612T3 (da) 1998-04-14
WO1993011749A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
IL104179A (en) Process for the preparation of solid pharmaceutical dispersions and solid pharmaceutical dispersions with improved solubility characteristics
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
HU912397D0 (en) Process for producing pyrazolo-pyridine derivatives
AU635021B2 (en) Extended release pharmaceutical formulations
ATE122668T1 (de) Diarylsubstituierte heterocyclische verbindung, ihre herstellung und arzneimittel und kosmetika daraus.
CS305091A3 (en) Pharmaceutical free of a solvent for per oral administration with delayed liberation of an active component and process for preparing thereof
EP0461630A3 (en) Production process of microspheres
GR3002601T3 (en) Microparticles comprising a biodegradable polymer controlling the release of an antimalarial drug, pharmaceutical compositions containing them and process for their preparation
MY106038A (en) 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents.
KR880009018A (ko) 3-l-피로글루타밀-l-티아졸리딘-4-카르복실산 및 이의 제법
AU3003189A (en) 7(2-(2-aminothiazol-4-yl)-2-hydroxyimino-acetamido)-3- methoxymethyl-3-cephem-4-carboxylate ester derivatives
HK65193A (en) Nicorandil-containing preparation for injection
JPS6263519A (ja) 貯蔵安定な固体経口投薬形の医薬組成物
MY114213A (en) Clavulanic acid salts
ATE288269T1 (de) Arzneizusammensetzungen und herstellungsverfahren von ergotalkaloidhaltigen arzneizusammensetzungen mit verzögerter wirkstoffabgabe und verbesserter bioverfügbarkeit
ES8500280A1 (es) Procedimiento para la produccion de un alcaloide peptidico 5's-(2r-butilo) del cornezuelo de centeno.
NO160258C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridazinonimin-derivater.
AU1370895A (en) 2'-deoxy-5-fluorouridine derivative, pharmaceutically acceptable salt thereof, process for producing the same, and antitumor drug
AU6703090A (en) New substituted benzothiazolinones, process for preparing these and pharmaceutical compositions containing them
DE69325531D1 (de) Oral anzuwendendes Arzneimittel bestehend aus Ibuprofen

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees